| Literature DB >> 29504482 |
Cristina Tassorelli1,2, Hans-Christoph Diener3, David W Dodick4, Stephen D Silberstein5, Richard B Lipton6, Messoud Ashina7, Werner J Becker8,9, Michel D Ferrari10, Peter J Goadsby11, Patricia Pozo-Rosich12,13, Shuu-Jiun Wang14.
Abstract
Background Quality clinical trials form an essential part of the evidence base for the treatment of headache disorders. In 1991, the International Headache Society Clinical Trials Standing Committee developed and published the first edition of the Guidelines for Controlled Trials of Drugs in Migraine. In 2008, the Committee published the first specific guidelines on chronic migraine. Subsequent advances in drug, device, and biologicals development, as well as novel trial designs, have created a need for a revision of the chronic migraine guidelines. Objective The present update is intended to optimize the design of controlled trials of preventive treatment of chronic migraine in adults, and its recommendations do not apply to trials in children or adolescents.Entities:
Keywords: Chronic migraine; clinical trials; drugs; headache; preventive treatment
Mesh:
Year: 2018 PMID: 29504482 DOI: 10.1177/0333102418758283
Source DB: PubMed Journal: Cephalalgia ISSN: 0333-1024 Impact factor: 6.292